NCT07014150View on ClinicalTrials.gov

Neoadjuvant Therapy of iIparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 10, 2025

Primary Completion Date

May 1, 2027

Study Completion Date

May 31, 2027

Conditions
Hepatocellular Carcinoma Resectable
Interventions
DRUG

Lenvatinib

daily,8mg/ day for less than 60kg, 12mg/ day for more than 60kg, for 9 weeks

DRUG

Iparomlimab and Tuvonralimab

7.5mg/kg, every 3 weeks, for 3cycles.

Trial Locations (1)

100000

Chinese Academy of Medical Sciences，Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER